Releases

Media coverage

Newsletter

Subscribe to our newsletter

Archive


Mar 2, 2016
We were deeply saddened to learn of the death of Holbrook Kohrt M.D., PhD on February 24th last. Holbrook was a highly valued member of the Scientific Advisory Board at Lytix Biopharma. Holbrook made a significant contribution to the field of tumour immunology. It was our privilege to work with Holbrook and his passing is a great loss to the scientific and clinical community.



Holbrook Kohrt

M.D., Ph.D., Assistant Professor of Medicine (Oncology); Stanford Cancer Institute. Dr. Kohrt investigated novel therapeutic strategies to enhance anti-tumor immunity, including the discovery of checkpoint inhibitors and cancer vaccine strategies. Dr. Kohrt was the co-director of the Cancer Immunotherapy Trials Network.

As a faculty member at Stanford, Dr. Kohrt was developing novel vaccine strategies which induce tumor antigen-specific immunity and improve graft-versus-tumor reactions without exacerbation of graft-versus-host disease. His studies also included efforts to identify and develop immunomodulatory antibodies targeting immune effector cells subsets, such as natural killer cells, which enhance the anti-tumor activity of tumor-targeting antibodies. Dr. Kohrt was a leader in the clinical development of agents including IL-15, IL-7, anti-CTLA-4, anti-CD137, anti-PD-1, anti-PD-L1, BTK inhibitors, and HPV-targeted and WT1-targeted vaccines.

Dr. Kohrt attended Stanford University Medical School, where he trained in Internal Medicine through the Clinical Investigator Pathway and completed a fellowship in Hematology and Oncology at Stanford with a research focus on preclinical models for novel immunomodulatory antibodies. During this time, he developed, validated, and nationally implemented a nomogram for risk prediction in early stage breast cancer. Dr. Kohrt received his Ph.D. in clinical trial design, biostatistics, and tumor immunology from Stanford under mentor Ron Levy with a thesis including the first report of an agonistic monoclonal antibody capable of enhancing the efficacy of tumor-targeting therapeutics. This antibody is now in five Phase 1/2 clinical trials.